Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

MAIA Biotechnology, Inc. (NASDAQ:MAIA) on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

The new data from the Phase 3 C-POST trial presented at ASCO 2025 demonstrated that cemiplimab (Libtayo) reduced the risk of ...

“These results show the continued promise of Libtayo in non-melanoma skin cancers,” said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. “Libtayo is the ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma ...